(NASDAQ: ALMS) Alumis's forecast annual revenue growth rate of 80.69% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.39%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.6%.
Alumis's revenue in 2026 is $24,050,000.On average, 13 Wall Street analysts forecast ALMS's revenue for 2026 to be $1,165,781,887, with the lowest ALMS revenue forecast at $0, and the highest ALMS revenue forecast at $2,671,185,993. On average, 11 Wall Street analysts forecast ALMS's revenue for 2027 to be $2,975,065,200, with the lowest ALMS revenue forecast at $0, and the highest ALMS revenue forecast at $9,362,506,905.
In 2028, ALMS is forecast to generate $21,391,111,831 in revenue, with the lowest revenue forecast at $10,383,790,350 and the highest revenue forecast at $41,269,823,592.